Gamco Investors INC. ET AL Grows Stake in Pfizer Inc. (NYSE:PFE)

Gamco Investors INC. ET AL increased its holdings in Pfizer Inc. (NYSE:PFE) by 12.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 765,364 shares of the biopharmaceutical company’s stock after buying an additional 87,621 shares during the period. Gamco Investors INC. ET AL’s holdings in Pfizer were worth $20,305,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in PFE. Norges Bank bought a new stake in shares of Pfizer during the 4th quarter valued at about $2,328,986,000. Charles Schwab Investment Management Inc. lifted its position in Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Pfizer during the fourth quarter valued at approximately $274,694,000. Massachusetts Financial Services Co. MA increased its holdings in shares of Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after buying an additional 5,350,381 shares during the last quarter. Finally, APG Asset Management N.V. raised its position in shares of Pfizer by 1,106.0% during the 4th quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock valued at $143,967,000 after buying an additional 5,153,257 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Stock Up 1.5 %

Shares of NYSE:PFE opened at $22.45 on Wednesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock’s 50-day moving average is $25.09 and its 200 day moving average is $26.31. The company has a market cap of $127.30 billion, a PE ratio of 15.92, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 earnings per share. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PFE. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, UBS Group lowered their price objective on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $31.07.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.